COST-EFFECTIVENESS OF BEVACIZUMAB AND RANIBIZUMAB AS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR PATIENTS WITH EYE DISORDERS: A SYSTEMATIC REVIEW. kjif 2024, 9 (1), 37-53. https://doi.org/10.26874/kjif.v9i1.658.